Market Overview

Oppenheimer Maintains Perform Rating, Does Not Set PT for Auxilium Pharmaceuticals

Related AUXL
Drug ETFs Attractive Buys On Pullback
Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Now Approved For The Concurrent Treatment Of Up To Two Affected Joints In The Same Hand In Dupuytren's Contracture Patients

In a quarterly update published earlier today, Oppenheimer Holdings maintained its Perform rating for Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) but did not set a price target.

Oppenheimer went on to say “On 5/10, AUXL reported adj. EPS of $0.06, above our $0.03 estimate, owing to higher revenues of $73.6M (vs. our $72.1M est.) while expenses were largely in line with our expectations. We highlight that Testim revenues of $57.9M were ahead of our $53.5M estimate and consensus of $54.4M while total Xiaflex revenues of $14.9M were slightly below expectations. We continue to anticipate positive phase III data for Xiaflex in Peyronie's in June, and believe the phase III trial design is much improved over the phase IIb trial, which produced statistically significant improvement in penile curvature in Xiaflex patients that received modeling (vs. placebo patients that received modeling). We slightly adjust our estimates.”

Auxilium Pharmaceuticals, Inc. closed yesterday at $17.45.

Latest Ratings for AUXL

Oct 2014MKM PartnersDowngradesBuyNeutral
Oct 2014MizuhoDowngradesBuyNeutral
Sep 2014RBC CapitalDowngradesOutperformSector Perform

View More Analyst Ratings for AUXL
View the Latest Analyst Ratings

Posted-In: Oppenheimer HoldingsAnalyst Color Reiteration Analyst Ratings


Related Articles (AUXL)

View Comments and Join the Discussion!

Partner Center